Tone mix
Week by week 52 weeks
Share of Ascendis Pharma A/S Ordinary Share's 126 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 24, 2026 · tone +100Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine+107
- Week of Feb 16, 2026 · tone -50Ascendis Pharma A/S (NASDAQ:ASND) Issues Quarterly Earnings Results, Misses Expectations By $0.58 EPS-93
- Week of Dec 29, 2025 · tone +100Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Buy" by Analysts+75
- Week of Sep 28, 2026 · tone -66Research Analysts' Downgrades for September 26th (AAMI, ABCB, ABCL, ABVX, AKAM, AMD, ASAN, ASND, ASTL, AXGN)-74
- Week of Sep 21, 2026 · tone +93Ascendis Pharma (NASDAQ: ASND) Severs Novo Nordisk Tie To Take Full Control Of TransCon Metabolic Pipeline+73
- Week of Oct 12, 2026 · tone +100Research Analysts' Upgrades for October 10th (ABEV, ABM, ACCV, AIRG, AIZ, ALB, ARLO, ASND, AZTA, BEAT)+73
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Ascendis Pharma A/S Ordinary Share in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 3 | +33 |
| Last 30 sessions | 15 | +38 |
| Last 90 sessions | 33 | +15 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletAscendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to AnalystsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to Analysts | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHead-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletAscendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head ReviewNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ascendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Review | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletAscendis Pharma: Once-Weekly TransCon CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ascendis Pharma: Once-Weekly TransCon CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletResearch Analysts' Upgrades for October 10th (ABEV, ABM, ACCV, AIRG, AIZ, ALB, ARLO, ASND, AZTA, BEAT)Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Research Analysts' Upgrades for October 10th (ABEV, ABM, ACCV, AIRG, AIZ, ALB, ARLO, ASND, AZTA, BEAT) | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Ascendis Pharma A/S Ordinary Share, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.